{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T17:36:15Z","timestamp":1788975375275,"version":"build-2803163510"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2021,10,18]],"date-time":"2021-10-18T00:00:00Z","timestamp":1634515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,18]],"date-time":"2021-10-18T00:00:00Z","timestamp":1634515200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-021-00563-8","type":"journal-article","created":{"date-parts":[[2021,10,18]],"date-time":"2021-10-18T08:16:12Z","timestamp":1634544972000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Viral infection\/reactivation during long-term follow-up in multiple myeloma patients with anti-BCMA CAR therapy"],"prefix":"10.1038","volume":"11","author":[{"given":"Di","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yimei","family":"Que","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menglei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhang","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8370-3232","authenticated-orcid":false,"given":"Liang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7274-6774","authenticated-orcid":false,"given":"Yi","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3215-3020","authenticated-orcid":false,"given":"Wen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shangkun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tongcun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5134-7133","authenticated-orcid":false,"given":"Chunrui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1332-9230","authenticated-orcid":false,"given":"Jianfeng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,18]]},"reference":[{"key":"563_CR1","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1200\/JCO.2018.77.8084","volume":"36","author":"JN Brudno","year":"2018","unstructured":"Brudno JN, Maric I, Hartman SD, Rose JJ, Wang M, Lam N, et al. T cells genetically modified to express an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma. J Clin Oncol. 2018;36:2267\u201380.","journal-title":"J Clin Oncol"},{"key":"563_CR2","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","volume":"380","author":"N Raje","year":"2019","unstructured":"Raje N, Berdeja J, Lin Y, Siegel D, Jagannath S, Madduri D, et al. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med. 2019;380:1726\u201337.","journal-title":"N Engl J Med"},{"key":"563_CR3","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","volume":"21","author":"S Lonial","year":"2020","unstructured":"Lonial S, Lee HC, Badros A, Trudel S, Nooka AK, Chari A, et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 2020;21:207\u201321.","journal-title":"Lancet Oncol"},{"key":"563_CR4","volume":"11","author":"C Li","year":"2021","unstructured":"Li C, Cao W, Que Y, Wang Q, Xiao Y, Gu C, et al. A phase I study of anti-BCMA CAR T cell therapy in relapsed\/refractory multiple myeloma and plasma cell leukemia. Clin Transl Med. 2021;11:e346.","journal-title":"Clin Transl Med"},{"key":"563_CR5","doi-asserted-by":"publisher","first-page":"2890","DOI":"10.1182\/blood.2020008936","volume":"137","author":"D Wang","year":"2021","unstructured":"Wang D, Wang J, Hu G, Wang W, Xiao Y, Cai H, et al. A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed\/refractory multiple myeloma. Blood 2021;137:2890\u2013901.","journal-title":"Blood"},{"key":"563_CR6","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1182\/blood-2003-06-2043","volume":"103","author":"AJ Novak","year":"2004","unstructured":"Novak AJ, Darce JR, Arendt BK, Harder B, Henderson K, Kindsvogel W, et al. Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival. Blood 2004;103:689\u201394.","journal-title":"Blood"},{"key":"563_CR7","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1182\/blood-2017-07-793760","volume":"131","author":"JA Hill","year":"2018","unstructured":"Hill JA, Li D, Hay KA, Green ML, Cherian S, Chen X, et al. Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy. Blood 2018;131:121\u201330.","journal-title":"Blood"},{"key":"563_CR8","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1182\/blood.2019004000","volume":"136","author":"JA Hill","year":"2020","unstructured":"Hill JA, Seo SK. How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies. Blood 2020;136:925\u201335.","journal-title":"Blood"},{"key":"563_CR9","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1086\/605664","volume":"49","author":"M Nucci","year":"2009","unstructured":"Nucci M, Anaissie E. Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents. Clin Infect Dis. 2009;49:1211\u201325.","journal-title":"Clin Infect Dis"},{"key":"563_CR10","doi-asserted-by":"publisher","first-page":"107","DOI":"10.3324\/haematol.2014.107714","volume":"100","author":"C Blimark","year":"2015","unstructured":"Blimark C, Holmberg E, Mellqvist UH, Landgren O, Bj\u00f6rkholm M, Hultcrantz M, et al. Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients. Haematologica 2015;100:107\u201313.","journal-title":"Haematologica"},{"key":"563_CR11","doi-asserted-by":"publisher","first-page":"e000862.","DOI":"10.1136\/jitc-2020-000862","volume":"8","author":"J Wei","year":"2020","unstructured":"Wei J, Zhao J, Han M, Meng F, Zhou J. SARS-CoV-2 infection in immunocompromised patients: humoral versus cell-mediated immunity. J Immunother Cancer. 2020;8:e000862.","journal-title":"J Immunother Cancer"},{"key":"563_CR12","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1182\/blood-2015-11-679639","volume":"127","author":"P Teira","year":"2016","unstructured":"Teira P, Battiwalla M, Ramanathan M, Barrett AJ, Ahn KW, Chen M, et al. Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis. Blood 2016;127:2427\u201338.","journal-title":"Blood"},{"key":"563_CR13","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1182\/blood.2020004907","volume":"136","author":"W Cao","year":"2020","unstructured":"Cao W, Wei J, Wang N, Xu H, Xiao M, Huang L, et al. Entecavir prophylaxis for hepatitis B virus reactivation in patients with CAR T-cell therapy. Blood 2020;136:516\u20139.","journal-title":"Blood"},{"key":"563_CR14","doi-asserted-by":"publisher","first-page":"100596","DOI":"10.1016\/j.blre.2019.100596","volume":"38","author":"JA Hill","year":"2019","unstructured":"Hill JA, Giralt S, Torgerson TR, Lazarus HM. CAR-T \u2013 and a side order of IgG, to go? \u2013 Immunoglobulin replacement in patients receiving CAR-T cell therapy. Blood Rev. 2019;38:100596.","journal-title":"Blood Rev"},{"key":"563_CR15","first-page":"e146743.","volume":"6","author":"CS Walti","year":"2021","unstructured":"Walti CS, Krantz EM, Maalouf J, Boonyaratanakornkit J, Keane-Candib J, Joncas-Schronce L, et al. Antibodies to vaccine preventable infections after CAR-T-cell therapy for B-cell malignancies. JCI Insight. 2021;6:e146743.","journal-title":"JCI Insight"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-021-00563-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-021-00563-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-021-00563-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T18:23:52Z","timestamp":1669919032000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-021-00563-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,18]]},"references-count":15,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2021,10]]}},"alternative-id":["563"],"URL":"https:\/\/doi.org\/10.1038\/s41408-021-00563-8","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,18]]},"assertion":[{"value":"29 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"G.H. and J.Z. are among inventors of patent applications related to the CT103A. W.W. and G.H. are employees of Nanjing IASO Therapeutics Ltd. and held interests in the company. J.Z. is a nonpaid member of the Scientific and Medical Advisory Board of Nanjing IASO Therapeutics Ltd. S.Z. and T.Z. are employees of Wuhan Bio\u2010Raid Biotechnology Co., Ltd. and held interests in the company. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"168"}}